RARE - Ultragenyx Pharmaceutical Inc Stock Price, Fair Value and News

44.85USD-0.21 (-0.47%)Market Closed

Market Summary

USD44.85-0.21

Market Closed

-0.47%

RARE Stock Price

View Fullscreen

RARE RSI Chart

RARE Valuation

Market Cap

3.7B

Price/Earnings (Trailing)

-6.08

Price/Sales (Trailing)

8.42

EV/EBITDA

-6.18

Price/Free Cashflow

-7.02

RARE Price/Sales (Trailing)

RARE Profitability

Operating Margin

88.59%

EBT Margin

-139.00%

Return on Equity

-437.28%

Return on Assets

-46.93%

Free Cashflow Yield

-14.24%

RARE Fundamentals

RARE Revenue

Revenue (TTM)

442.6M

Rev. Growth (Yr)

8.3%

Rev. Growth (Qtr)

-14.57%

RARE Earnings

Earnings (TTM)

-613.4M

Earnings Growth (Yr)

-4.09%

Earnings Growth (Qtr)

-38.55%

Breaking Down RARE Revenue

Last 7 days

5.4%

Last 30 days

10.7%

Last 90 days

1.4%

Trailing 12 Months

6.8%

How does RARE drawdown profile look like?

RARE Financial Health

Current Ratio

2.43

RARE Investor Care

Shares Dilution (1Y)

17.40%

Diluted EPS (TTM)

-7.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	442.6M	0	0	0
2023	383.9M	402.9M	410.2M	434.2M
2022	331.9M	334.3M	343.4M	363.3M
2021	334.1M	359.4M	359.6M	351.4M
2020	121.9M	159.4M	215.1M	271.0M
2019	59.0M	70.3M	84.4M	103.7M
2018	13.0M	25.8M	37.3M	51.5M
2017	0	0	331.0K	2.4M
2016	0	322.0K	370.0K	282.0K
2014	0	331.0K	0	0
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

CEO	Dr. Emil D. Kakkis M.D., Ph.D.
WEBSITE	ultragenyx.com
INDUSTRY	Biotechnology
EMPLOYEES	1311

Ultragenyx Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for Ultragenyx Pharmaceutical Inc? What does RARE stand for in stocks?

RARE is the stock ticker symbol of Ultragenyx Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ultragenyx Pharmaceutical Inc (RARE)?

As of Fri Jul 26 2024, market cap of Ultragenyx Pharmaceutical Inc is 3.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RARE stock?

You can check RARE's fair value in chart for subscribers.

Is Ultragenyx Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether RARE is over valued or under valued. Whether Ultragenyx Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Ultragenyx Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RARE.

What is Ultragenyx Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, RARE's PE ratio (Price to Earnings) is -6.08 and Price to Sales (PS) ratio is 8.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RARE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ultragenyx Pharmaceutical Inc's stock?

In the past 10 years, Ultragenyx Pharmaceutical Inc has provided 0.008 (multiply by 100 for percentage) rate of return.